CO5680443A2 - Derivados de bencimidazol, composiciones que los contienen, preparacion de los mismos y usos de los mismos - Google Patents

Derivados de bencimidazol, composiciones que los contienen, preparacion de los mismos y usos de los mismos

Info

Publication number
CO5680443A2
CO5680443A2 CO06028452A CO06028452A CO5680443A2 CO 5680443 A2 CO5680443 A2 CO 5680443A2 CO 06028452 A CO06028452 A CO 06028452A CO 06028452 A CO06028452 A CO 06028452A CO 5680443 A2 CO5680443 A2 CO 5680443A2
Authority
CO
Colombia
Prior art keywords
alkyl
heterocyclyl
cycloalkenyl
cycloalkyl
alkynyl
Prior art date
Application number
CO06028452A
Other languages
English (en)
Spanish (es)
Inventor
Ziping Liu
Daniel Page
Christopher Walpole
Hua Yang
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO5680443A2 publication Critical patent/CO5680443A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08Radicals containing only hydrogen and carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14Radicals substituted by nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CO06028452A 2003-09-26 2006-03-22 Derivados de bencimidazol, composiciones que los contienen, preparacion de los mismos y usos de los mismos CO5680443A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0302573A SE0302573D0 (sv) 2003-09-26 2003-09-26 Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof

Publications (1)

Publication Number Publication Date
CO5680443A2 true CO5680443A2 (es) 2006-09-29

Family

ID=29246982

Family Applications (1)

Application Number Title Priority Date Filing Date
CO06028452A CO5680443A2 (es) 2003-09-26 2006-03-22 Derivados de bencimidazol, composiciones que los contienen, preparacion de los mismos y usos de los mismos

Country Status (33)

Country Link
US (1) US8633235B2 (https=)
EP (1) EP1670769B1 (https=)
JP (1) JP4896721B2 (https=)
KR (1) KR101170184B1 (https=)
CN (2) CN1886379A (https=)
AR (1) AR045819A1 (https=)
AT (1) ATE430135T1 (https=)
AU (1) AU2004276062B2 (https=)
BR (1) BRPI0414780B8 (https=)
CA (1) CA2539738C (https=)
CO (1) CO5680443A2 (https=)
CY (1) CY1110332T1 (https=)
DE (1) DE602004020907D1 (https=)
DK (1) DK1670769T3 (https=)
ES (1) ES2324669T3 (https=)
HR (1) HRP20090388T1 (https=)
IL (1) IL174215A0 (https=)
IS (1) IS8422A (https=)
MX (1) MXPA06003197A (https=)
MY (1) MY140630A (https=)
NO (1) NO20061839L (https=)
NZ (1) NZ545736A (https=)
PL (1) PL1670769T3 (https=)
PT (1) PT1670769E (https=)
RU (1) RU2346938C2 (https=)
SA (1) SA04250310B1 (https=)
SE (1) SE0302573D0 (https=)
SI (1) SI1670769T1 (https=)
TW (1) TW200521117A (https=)
UA (1) UA86776C2 (https=)
UY (1) UY28536A1 (https=)
WO (1) WO2005030732A1 (https=)
ZA (3) ZA200602446B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1558252B1 (en) 2002-08-02 2007-10-10 Merck & Co., Inc. Substituted furo [2,3-b]pyridine derivatives
SE0302573D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
EP1797077B1 (en) 2004-09-24 2012-02-15 AstraZeneca AB Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof i
CN101052639B (zh) * 2004-09-24 2010-10-27 阿斯利康(瑞典)有限公司 苯并咪唑衍生物、含有它们的组合物、其制备方法和其用途
AU2005287427B2 (en) * 2004-09-24 2009-03-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof I
CA2582507A1 (en) * 2004-09-24 2006-03-30 Astrazeneca Ab Compounds, compositions containing them, preparation thereof and uses thereof iii
ES2318556T3 (es) 2004-11-02 2009-05-01 Pfizer, Inc. Derivados de sulfonil bencimidazol.
EP1912930A4 (en) * 2005-07-29 2010-04-14 Astrazeneca Ab PROCESS FOR PREPARING GEMINAL ((DIFLUORCYCLOALKYL) METHYL) AMINE
TW200745049A (en) 2006-03-23 2007-12-16 Astrazeneca Ab New crystalline forms
TW200808769A (en) 2006-04-18 2008-02-16 Astrazeneca Ab Therapeutic compounds
US20080139846A1 (en) * 2006-09-01 2008-06-12 Astrazeneca Ab New Process 298
US8236841B2 (en) * 2006-09-13 2012-08-07 Kyowa Hakko Kirin Co., Ltd. Fused heterocycle derivative
US20110086853A1 (en) * 2009-10-08 2011-04-14 William Brown Therapeutic Compounds
RU2414899C1 (ru) * 2009-12-29 2011-03-27 Аверин Константин Михайлович Средства для лечения рассеянного склероза
RU2454234C1 (ru) * 2011-03-16 2012-06-27 Константин Михайлович Аверин Соли 1,3-диэтилбензимидазолия - иммуностимулирующие средства и фармацевтические композиции на их основе
WO2013188490A1 (en) * 2012-06-13 2013-12-19 Cytec Technology Corp. Stabilizer compositions containing substituted chroman compounds and methods of use
HUE032306T2 (en) 2012-06-26 2017-09-28 Bayer Pharma AG N- [4- (quinolin-4-yloxy) cyclohexyl (methyl)] (hetero) arylcarboxamides as androgen receptor antagonists, their production and use as pharmaceutical products
EP3762379A1 (en) 2018-03-07 2021-01-13 Bayer Aktiengesellschaft Identification and use of erk5 inhibitors
WO2020234103A1 (en) 2019-05-21 2020-11-26 Bayer Aktiengesellschaft Identification and use of kras inhibitors
CN112010789A (zh) * 2019-05-31 2020-12-01 中国科学院上海药物研究所 乙烯基磺酰胺或乙烯基酰胺类化合物及其制备方法和用途
GB202019335D0 (en) * 2020-12-08 2021-01-20 Artelo Biosciences Ltd Pharmaceutical compositions
KR102771568B1 (ko) * 2022-03-04 2025-02-24 삼진제약주식회사 신규한 헤테로 고리 화합물 및 이를 포함하는 약학적 조성물

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1604908A (en) 1965-06-24 1971-05-15 Substd benzimidazoles - with anthelmintic,fungicidal activity and some with antiviral and antibacterial activity
FR5354M (https=) 1965-09-10 1967-09-11
US5387600A (en) 1992-07-30 1995-02-07 Fuji Photo Film Co., Ltd. Treating arteriosclerosis using benzimidazole compositions
DE4237617A1 (de) 1992-11-06 1994-05-11 Bayer Ag Verwendung von substituierten Benzimidazolen
DE4237557A1 (de) 1992-11-06 1994-05-11 Bayer Ag Substituierte Benzimidazole
DE4237597A1 (de) 1992-11-06 1994-05-11 Bayer Ag Substituierte Benzimidazole
WO1997024334A1 (en) 1995-12-28 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
TW453999B (en) * 1997-06-27 2001-09-11 Fujisawa Pharmaceutical Co Benzimidazole derivatives
US6348032B1 (en) 1998-11-23 2002-02-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with benzimidazole derivatives
US6534535B1 (en) 1999-08-12 2003-03-18 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
CZ2002959A3 (cs) 1999-09-17 2002-07-17 Millennium Pharmaceuticals, Inc. Inhibitory faktoru Xa
US6720317B1 (en) 1999-09-17 2004-04-13 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
US7115645B2 (en) 2000-01-14 2006-10-03 Schering Aktiengesellschaft 1,2 diarylbenzimidazoles and their pharmaceutical use
EE05515B1 (et) * 2000-01-14 2012-02-15 Schering@Aktiengesellschaft 1 2 diarlbensimidasoolid mikrogliia aktivatsiooniga seotud haiguste raviks
US7329679B2 (en) * 2000-01-27 2008-02-12 Schering Aktiengesellschaft 1,2 Diarylbenzimidazoles and their pharmaceutical use
WO2001064642A2 (en) 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
WO2002046168A1 (en) 2000-12-07 2002-06-13 Astrazeneca Ab Therapeutic benzimidazole compounds
SE0101387D0 (sv) * 2001-04-20 2001-04-20 Astrazeneca Ab Novel compounds
WO2002100833A1 (en) 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Rho KINASE INHIBITORS
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
SE0301699D0 (sv) * 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0301701D0 (sv) 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
WO2005007625A2 (en) 2003-07-14 2005-01-27 The University Of Tennessee Research Foundation Heterocyclic amides with anti-tuberculosis activity
WO2005021547A2 (en) 2003-08-28 2005-03-10 Pharmaxis Pty Ltd. Heterocyclic cannabinoid cb2 receptor antagonists
SE0302573D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302570D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302571D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302572D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
US20060035884A1 (en) 2004-05-20 2006-02-16 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
WO2006009876A2 (en) 2004-06-17 2006-01-26 Cengent Therapeutics, Inc. Trisubstituted nitrogen modulators of tyrosine phosphatases
CA2573426C (en) 2004-07-30 2015-11-17 Exelixis, Inc. Pyrrole derivatives as pharmaceutical agents
US20060052421A1 (en) 2004-09-09 2006-03-09 Eastman Kodak Company Conjugation agent
JP2008514589A (ja) 2004-09-24 2008-05-08 アストラゼネカ・アクチエボラーグ 化合物、それらを含有する組成物、それらの製造及びそれらの使用iiii
CA2582507A1 (en) 2004-09-24 2006-03-30 Astrazeneca Ab Compounds, compositions containing them, preparation thereof and uses thereof iii
AU2005287427B2 (en) 2004-09-24 2009-03-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof I
JP2008514591A (ja) 2004-09-24 2008-05-08 アストラゼネカ・アクチエボラーグ ベンゾイミダゾール誘導体及びカンナビノイド受容体リガンドとしてのその使用
EP1794150A1 (en) 2004-09-24 2007-06-13 AstraZeneca AB Benzimidazole derivatives and their use as cannabinoid receptor ligands I
EP1797077B1 (en) * 2004-09-24 2012-02-15 AstraZeneca AB Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof i
JP2008514590A (ja) 2004-09-24 2008-05-08 アストラゼネカ・アクチエボラーグ ベンゾイミダゾール誘導体、それを含む組成物、その製造方法及びその使用
WO2006033633A1 (en) 2004-09-24 2006-03-30 Astrazeneca Ab Compounds, compositions containing them, preparations thereof and uses thereof ii
ES2318556T3 (es) 2004-11-02 2009-05-01 Pfizer, Inc. Derivados de sulfonil bencimidazol.
WO2006078941A2 (en) 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Novel sirtuin activating compounds and methods of use thereof
TW200745049A (en) 2006-03-23 2007-12-16 Astrazeneca Ab New crystalline forms
TW200808769A (en) 2006-04-18 2008-02-16 Astrazeneca Ab Therapeutic compounds
TW200808772A (en) 2006-06-13 2008-02-16 Astrazeneca Ab Therapeutic compounds

Also Published As

Publication number Publication date
AU2004276062B2 (en) 2008-05-22
ZA200702226B (en) 2009-01-28
ZA200702131B (en) 2008-08-27
US8633235B2 (en) 2014-01-21
BRPI0414780B8 (pt) 2021-05-25
CN1886379A (zh) 2006-12-27
UY28536A1 (es) 2005-04-29
CN102010373A (zh) 2011-04-13
WO2005030732A1 (en) 2005-04-07
HK1089436A1 (en) 2006-12-01
PL1670769T3 (pl) 2009-09-30
ATE430135T1 (de) 2009-05-15
BRPI0414780B1 (pt) 2018-10-23
EP1670769B1 (en) 2009-04-29
MXPA06003197A (es) 2006-06-23
JP2007506721A (ja) 2007-03-22
RU2346938C2 (ru) 2009-02-20
AU2004276062A1 (en) 2005-04-07
SI1670769T1 (sl) 2009-10-31
US20080207612A1 (en) 2008-08-28
PT1670769E (pt) 2009-07-09
DK1670769T3 (da) 2009-08-10
EP1670769A1 (en) 2006-06-21
ES2324669T3 (es) 2009-08-12
SE0302573D0 (sv) 2003-09-26
CY1110332T1 (el) 2015-01-14
CA2539738C (en) 2011-11-22
BRPI0414780A (pt) 2006-11-21
HRP20090388T1 (hr) 2009-08-31
IL174215A0 (en) 2006-08-01
NZ545736A (en) 2009-11-27
ZA200602446B (en) 2007-09-26
CA2539738A1 (en) 2005-04-07
TW200521117A (en) 2005-07-01
UA86776C2 (ru) 2009-05-25
MY140630A (en) 2010-01-15
KR20070001052A (ko) 2007-01-03
RU2006113371A (ru) 2007-11-10
DE602004020907D1 (de) 2009-06-10
IS8422A (is) 2006-04-21
SA04250310B1 (ar) 2009-01-19
AR045819A1 (es) 2005-11-16
NO20061839L (no) 2006-06-26
KR101170184B1 (ko) 2012-07-31
JP4896721B2 (ja) 2012-03-14

Similar Documents

Publication Publication Date Title
CO5680443A2 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion de los mismos y usos de los mismos
CO5660260A2 (es) Derivados de benzimidazol, composiciones que los contienen, preparacion y el uso de los mismos
AR045595A1 (es) Composiciones utiles como inhibidores de proteinas quinasas
AR063015A1 (es) Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos en el tratamiento del cancer
AR053652A1 (es) Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas
AR083058A1 (es) Compuestos de estructura de imidazotriazinona
CO6150164A2 (es) Derivados de 2-metilmorfolina pirido-,pirazo-ypirimido-pirimidina como inhibidores de mtor
CO5660261A2 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion de estos y usos de estos
AR046711A1 (es) 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones
AR052943A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
CO5700780A2 (es) Derivados de quinolina como inhibidores, selectivos, de de fosfodiesterasa pde 4b
NO20063821L (no) Kinolinderivater for anvendelse som mykobakterielle inhibitorer
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
CL2011002016A1 (es) Compuestos derivados de benzimidazol con actividad inhibidora de la funcion de la proteina ns5a codificada por el virus de la hepatitis c (vhc); composicion farmaceutica que los comprende; utiles en el tratamiento de una infeccion por el virus de la hepatitis c (vhc).
AR074171A1 (es) Derivados de pirazolopiridina, composicion farmaceutica que los comprende y su uso en el tratamiento de afecciones mediadas por pkctheta
AR053699A1 (es) Derivados de tetrahidro-1h-pirido[4,3-b]indoles como ligandos de receptores cb1
PE20061439A1 (es) DERIVADOS DE 2-AMIDO-6-AMINO-8-OXO-PURINA COMO MODULADORES DEL RECEPTOR Toll (TLR)
AR040074A1 (es) Tiazolidinonas, su preparacion y su uso como medicamentos, e intermediarios para la preparacion de dichos compuestos
AR055150A1 (es) Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
CO5590916A2 (es) Dicetopiperacinas sustituidas como antagonistas de oxitocina
AR045822A1 (es) Derivados de bencimidazol, composiciones que los contienen preparacion de los mismos y usos de los mismos
AR077525A1 (es) 4-aril-butan-1,3-diamidas y composiciones farmaceuticas
PE20071137A1 (es) Derivados de 8-piracin-s-espiropirimidintriona oxaquinolina como agentes antibacterianos
AR040126A1 (es) Compuesto de fenilsulfonilo, composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento

Legal Events

Date Code Title Description
FC Application refused